Halámková, J.; Bohovicová, L.; Pehalová, L.; Goněc, R.; Staněk, T.; Kazda, T.; Mouková, L.; Krákorová, D.A.; Kozáková, Š.; Svoboda, M.;
et al. Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients. Cancers 2022, 14, 1699.
https://doi.org/10.3390/cancers14071699
AMA Style
Halámková J, Bohovicová L, Pehalová L, Goněc R, Staněk T, Kazda T, Mouková L, Krákorová DA, Kozáková Š, Svoboda M,
et al. Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients. Cancers. 2022; 14(7):1699.
https://doi.org/10.3390/cancers14071699
Chicago/Turabian Style
Halámková, Jana, Lucia Bohovicová, Lucie Pehalová, Roman Goněc, Teodor Staněk, Tomáš Kazda, Lucie Mouková, Dagmar Adámková Krákorová, Šárka Kozáková, Marek Svoboda,
and et al. 2022. "Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients" Cancers 14, no. 7: 1699.
https://doi.org/10.3390/cancers14071699
APA Style
Halámková, J., Bohovicová, L., Pehalová, L., Goněc, R., Staněk, T., Kazda, T., Mouková, L., Krákorová, D. A., Kozáková, Š., Svoboda, M., Demlová, R., & Kiss, I.
(2022). Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients. Cancers, 14(7), 1699.
https://doi.org/10.3390/cancers14071699
